PHAR Key Statistics, Chart & Performance
The current stock price of PHAR is 16.75 USD. In the past month the price increased by 13.95%. In the past year, price increased by 116.97%.
PHAR Latest News, Press Relases and Analysis
PHAR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About PHAR
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
PHARMING GROUP NV - ADR
Darwinweg 24
Leiden ZUID-HOLLAND 2333 CR NL
CEO: Sijmen de Vries
Employees: 426
Phone: 31715247400
PHARMING GROUP NV - ADR / PHAR FAQ
Can you describe the business of PHARMING GROUP NV - ADR?
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
What is the stock price of PHARMING GROUP NV - ADR today?
The current stock price of PHAR is 16.75 USD. The price decreased by -3.46% in the last trading session.
What is the dividend status of PHARMING GROUP NV - ADR?
PHAR does not pay a dividend.
What is the ChartMill rating of PHARMING GROUP NV - ADR stock?
PHAR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Would investing in PHARMING GROUP NV - ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHAR.
What is the market capitalization of PHAR stock?
PHARMING GROUP NV - ADR (PHAR) has a market capitalization of 1.15B USD. This makes PHAR a Small Cap stock.
What is the next earnings date for PHAR stock?
PHARMING GROUP NV - ADR (PHAR) will report earnings on 2026-03-11, after the market close.
PHAR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PHAR. When comparing the yearly performance of all stocks, PHAR is one of the better performing stocks in the market, outperforming 94.66% of all stocks.
PHAR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PHAR. PHAR is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
PHAR Financial Highlights
Over the last trailing twelve months PHAR reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS increased by 96.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.03% | ||
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| Debt/Equity | 0.46 |
PHAR Forecast & Estimates
14 analysts have analysed PHAR and the average price target is 18.35 USD. This implies a price increase of 9.56% is expected in the next year compared to the current price of 16.75.
For the next year, analysts expect an EPS growth of 227.95% and a revenue growth 18.75% for PHAR